AC
TEVA icon

Addison Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Addison Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-41,413
Closed -$422K – 113
2023
Q3 		$422K Sell
41,413
-825
-2% -$7.68K 0.33% 62
2023
Q2 		$318K Sell
42,238
-275
-0.6% -$2.23K 0.23% 80
2023
Q1 		$376K Hold
42,513
– – 0.28% 69
2022
Q4 		$388K Hold
42,513
– – 0.24% 84
2022
Q3 		$343K Hold
42,513
– – 0.21% 90
2022
Q2 		$320K Sell
42,513
-150
-0.4% -$1.31K 0.19% 102
2022
Q1 		$401K Sell
42,663
-280
-0.7% -$2.34K 0.19% 99
2021
Q4 		$344K Sell
42,943
-35
-0.1% -$316 0.15% 100
2021
Q3 		$419K Sell
42,978
-50
-0.1% -$468 0.19% 75
2021
Q2 		$426K Buy
43,028
+5,240
+14% +$55.5K 0.21% 76
2021
Q1 		$436K Hold
37,788
– – 0.24% 71
2020
Q4 		$365K Sell
37,788
-690
-2% -$6.61K 0.22% 74
2020
Q3 		$347K Sell
38,478
-103
-0.3% -$1.09K 0.24% 70
2020
Q2 		$476K Sell
38,581
-3,725
-9% -$42.1K 0.37% 57
2020
Q1 		$380K Buy
42,306
+4,000
+10% +$41K 0.28% 73
2019
Q4 		$375K Sell
38,306
-4,330
-10% -$38.7K 0.25% 85
2019
Q3 		$293K Sell
42,636
-130
-0.3% -$996 0.21% 98
2019
Q2 		$395K Sell
42,766
-15,567
-27% -$188K 0.28% 79
2019
Q1 		$915K Sell
58,333
-1,440
-2% -$25.4K 0.7% 46
2018
Q4 		$922K Sell
59,773
-7,832
-12% -$161K 0.82% 41
2018
Q3 		$1.46M Buy
67,605
+15,571
+30% +$361K 1.09% 33
2018
Q2 		$1.26M Sell
52,034
-320
-0.6% -$6.53K 0.98% 33
2018
Q1 		$895K Buy
52,354
+135
+0.3% +$2.64K 0.73% 45
2017
Q4 		$990K Sell
52,219
-4,455
-8% -$67K 0.78% 42
2017
Q3 		$997K Buy
56,674
+1,493
+3% +$33.6K 0.88% 42
2017
Q2 		$1.83M Sell
55,181
-1,775
-3% -$54.9K 1.46% 26
2017
Q1 		$1.83M Buy
56,956
+1,100
+2% +$37.5K 1.47% 27
2016
Q4 		$2.02M Buy
55,856
+12,930
+30% +$516K 1.78% 22
2016
Q3 		$1.98M Sell
42,926
-88
-0.2% -$4.59K 1.73% 20
2016
Q2 		$2.16M Sell
43,014
-11,309
-21% -$602K 1.95% 14
2016
Q1 		$2.91M Sell
54,323
-1,961
-3% -$115K 2.22% 8
2015
Q4 		$3.69M Buy
56,284
+8,795
+19% +$544K 2.89% 3
2015
Q3 		$2.68M Buy
47,489
+10,750
+29% +$697K 2.49% 8
2015
Q2 		$2.17M Sell
36,739
-325
-0.9% -$20K 1.98% 20
2015
Q1 		$2.31M Sell
37,064
-135
-0.4% -$7.85K 1.88% 19
2014
Q4 		$2.14M Sell
37,199
-3,065
-8% -$171K 1.8% 21
2014
Q3 		$2.16M Sell
40,264
-510
-1% -$27K 1.9% 22
2014
Q2 		$2.14M Sell
40,774
-125
-0.3% -$6.39K 1.85% 22
2014
Q1 		$2.16M Buy
40,899
+649
+2% +$30K 1.84% 16
2013
Q4 		$1.61M Buy
+40,250
New +$1.58M 1.48% 27

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Addison Capital's TEVA Position: Q4 2023 in Review

Addison Capital sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 41,413 shares — an estimated $422K sold.

Addison Capital first reported a position in TEVA in Q4 2013 and held it in 40 quarters. The position peaked at $3.69M in Q4 2015. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • Addison Capital reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Addison Capital sold 41,413 Teva Pharmaceuticals shares in Q4 2023, an estimated $422K.
  • Addison Capital first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 40 quarters.
  • Addison Capital's Teva Pharmaceuticals position peaked at $3.69M in Q4 2015.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Addison Capital's 13F filing for Q4 2023, filed 8 Feb 2024.